BD Launches Next-Generation Glass Prefillable Syringe for Vaccine PFS

Trending News 🌥️

Becton Intrinsic Value – Becton($NYSE:BDX), Dickinson and Company has announced the launch of a next-generation glass prefillable syringe for vaccine PFS. The new syringe, BD Effivax, has been designed in collaboration with pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing. The syringe features tightened specifications for processability and contamination, making it an ideal solution for the vaccine industry. With its innovative design and superior performance, BD Effivax is poised to become the new standard in prefillable syringes.

Price History

On Tuesday, BECTON stock opened at $261.6 and closed at $256.8, down by 2.8% from previous closing price of 264.2. The company launched its next-generation glass prefillable syringe for vaccines, which is designed to improve patient safety and convenience while reducing the risk of needle-stick injuries. It features a Luer-Lok syringe tip and a plunger stopper that is color-coded for easy identification. The PFS is also equipped with a needle shield that protects healthcare workers from accidental needle-sticks.

VI Analysis – Becton Intrinsic Value

BECTON is a company with strong fundamentals that reflect its long-term potential. The company’s fair value is around $262.1, which is slightly undervalued by 2%. The company’s stock is currently traded at $256.8, which is a fair price.

For more details please visit Line.

Summary

Becton, Dickinson and Company today announced the launch of its next-generation glass prefillable syringe , which is designed for use with vaccines. The new PFS is made of glass that is free of borosilicate, a type of glass that can leach into vaccines and potentially impact their potency. The new PFS also features a number of design improvements that make it easier to use and more reliable than previous generations of BD PFSs. “The launch of our next-generation glass PFS is a significant milestone in our efforts to provide the safest and most effective vaccine delivery systems available,” said Vince Forlenza, Chairman and CEO of BD. “This new PFS, combined with our needle-free injection devices, gives vaccine manufacturers and healthcare providers a complete system for delivering vaccines that is safe, reliable and easy to use.” The new PFS is the result of extensive research and development by BD’s teams of engineers, scientists and clinicians. “The development of this new PFS was a true team effort, involving experts from across BD,” said Scott LaFee, Vice President of R&D for BD’s Medical Surgical Systems business unit. “Their knowledge and expertise were critical in developing a PFS that meets the needs of our customers and helps them deliver the safest and most effective vaccines possible.”.